Aberrant promoter methylation of retinoic acid receptor-b 2 (RAR-b 2 ) is frequently detected in hepatitis B virus (HBV)-positive hepatocellular carcinoma (HCC); however, the mechanism of methylation and its biological significance are unknown. This study showed that HBx, the principal oncogene product of HBV, induced promoter hypermethylation of RAR-b 2 via upregulation of DNA methyltransferases 1 and 3a, resulting in downregulation of its expression in human HCC cells. In addition, HBx abolished the potential of retinoic acid (RA) to downregulate levels of G 1 -checkpoint regulators including p16, p21 and p27, resulting in activation of E2F1 in the presence of RA. As a consequence, HBx-expressing cells were less susceptible to RA-induced cell growth inhibition compared with control cells. These effects almost completely disappeared when levels of RAR-b 2 in HBx-expressing cells were restored by treatment with a universal DNA methylation inhibitor, 5-aza-29-deoxycytidine. As RAR-b 2 is a major executor of the anti-tumour potential of RA, its epigenetic downregulation by HBx is likely to be an important step during HBV-mediated tumorigenesis.
INTRODUCTIONRetinoids are vitamin A derivatives and analogues that are involved in many important biological processes, including vision, morphogenesis, differentiation, growth, metabolism and cellular homeostasis (De Luca, 1991). In addition, they act as inhibitors of carcinogenesis by blocking the promotion of initiated or transformed cells by three mechanisms: induction of apoptosis, arrest of further growth of abnormal cells and induction of abnormal cells to differentiate back to normal (Hansen et al., 2000). These effects are executed mainly by regulating gene expression primarily through two classes of nuclear receptors, including retinoic acid (RA) receptors (RARs) and retinoid X receptors (RXRs) (Chambon, 1996). As either homodimers or heterodimers, RARs and RXRs modulate the expression of target genes by acting on the RA response element (RARE) located on the promoter regions of target genes.RAR-b contains four isoforms with different affinities to retinoids and different biological functions (Chambon, 1996). In particular, RAR-b 2 has attracted attention as a major executor of the anti-tumour potential of retinoids in a wide variety of cancers (Houle et al., 1993;Xu, 2007). Loss of RAR-b 2 is closely associated with retinoid resistance during tumorigenesis (Gebert et al., 1991;Hoffman et al., 1996;Hu et al., 1991;Xu et al., 1994). In addition, exogenous introduction of RAR-b 2 into cervical, breast and lung cancer cells enhances cell responsiveness to growth inhibition and induction of apoptosis by retinoids (Seewaldt et al., 1995; Si et al., 1996). Therefore, its loss of function is now considered to play a critical role in tumorigenesis. Aberrant promoter methylation of RAR-b 2 , which can lead to transcriptional downregulation of its expression, is frequently detected in human malignant tumours including hepatocellular carcinoma (HCC) (Lee et al., 2003;Yang et...